Systematic review: extracorporeal bio-artificial liver-support system for liver failure
- PMID: 26201519
- DOI: 10.1007/s12072-012-9352-9
Systematic review: extracorporeal bio-artificial liver-support system for liver failure
Abstract
Background: Orthotopic liver transplantation (OLT) is the only effective long-term treatment for liver failure by now. However, it is not yet a perfect choice due to donor-organ shortage and the need of a lifelong immunosuppressive therapy. Therefore, it is necessary to find a new approach to fighting the disease. Several published clinical trials have reported the therapeutic effect of bio-artificial liver (BAL) for liver failure.
Objective: To overview and evaluate the current clinical application and outcomes of extracorporeal BAL support system during the past 15 years.
Methods: Relevant studies were retrieved from PubMed and Cochrane Library databases. Independent assessments and the final consensus decision were performed by three independent reviewers. Acceptable study designs included randomized controlled trials, controlled clinical trials, and case reports. A total of 31 studies were tabulated and critically appraised in terms of characteristics, methods, and outcomes.
Results: There was a trend of falling into the normal ranges with the clinical and biochemical parameters after the BAL treatment. The neurological status of most patients was improved or stabilized during BAL treatment as well. No significant effect on survival could be seen after the BAL treatment.
Conclusions: Although BAL system proved to be a success in some clinical cases reported, it still needs to be improved greatly.
Keywords: Bio-artificial liver; Clinical trial; Liver failure; Systematic review.
Similar articles
-
Bioartificial liver support systems for acute liver failure: A systematic review and meta-analysis of the clinical and preclinical literature.World J Gastroenterol. 2019 Jul 21;25(27):3634-3648. doi: 10.3748/wjg.v25.i27.3634. World J Gastroenterol. 2019. PMID: 31367162 Free PMC article.
-
Extracorporeal tissue engineered liver-assist devices.Annu Rev Biomed Eng. 2000;2:607-32. doi: 10.1146/annurev.bioeng.2.1.607. Annu Rev Biomed Eng. 2000. PMID: 11701525 Review.
-
Treatment of patients with hepatic failure: the difficult place of liver support systems.J Hepatol. 2004 Oct;41(4):694-5. doi: 10.1016/j.jhep.2004.08.004. J Hepatol. 2004. PMID: 15464258 Clinical Trial.
-
['Artificial support in case of hepatic failure'; a report from the Dutch Health Council].Ned Tijdschr Geneeskd. 2005 Jan 29;149(5):221-3. Ned Tijdschr Geneeskd. 2005. PMID: 15719830 Dutch.
-
How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?Int J Evid Based Healthc. 2008 Mar;6(1):78-110. doi: 10.1111/j.1744-1609.2007.00098.x. Int J Evid Based Healthc. 2008. PMID: 21631815
Cited by
-
Immortalization Reversibility in the Context of Cell Therapy Biosafety.Int J Mol Sci. 2023 Apr 23;24(9):7738. doi: 10.3390/ijms24097738. Int J Mol Sci. 2023. PMID: 37175444 Free PMC article. Review.
-
Effectiveness of granulocyte colony-stimulating factor for patients with acute-on-chronic liver failure: a meta-analysis.Ann Saudi Med. 2021 Nov-Dec;41(6):383-391. doi: 10.5144/0256-4947.2021.383. Epub 2021 Dec 2. Ann Saudi Med. 2021. PMID: 34873932 Free PMC article.
-
Longitudinal effects of modified creatinine index on all-cause mortality in individuals receiving hemodialysis treatment.Ann Saudi Med. 2021 Nov-Dec;41(6):361-368. doi: 10.5144/0256-4947.2021.361. Epub 2021 Dec 2. Ann Saudi Med. 2021. PMID: 34873933 Free PMC article.
-
Pluripotent-Stem-Cell-Derived Hepatic Cells: Hepatocytes and Organoids for Liver Therapy and Regeneration.Cells. 2020 Feb 12;9(2):420. doi: 10.3390/cells9020420. Cells. 2020. PMID: 32059501 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Miscellaneous